Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARTIA XT vs CALAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diltiazem, a benzothiazepine calcium channel blocker, inhibits calcium ion influx across cardiac and vascular smooth muscle cells during depolarization, leading to vasodilation and reduced myocardial contractility and conduction velocity, particularly at the AV node.
Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.
FDA-approved: hypertension,FDA-approved: chronic stable angina,FDA-approved: atrial fibrillation or flutter (rate control),Off-label: prevention of migraine,Off-label: anal fissure (topical)
Angina pectoris (chronic stable, vasospastic, unstable),Essential hypertension,Supraventricular tachyarrhythmias (e.g., atrial fibrillation, atrial flutter, PSVT)
Diltiazem hydrochloride extended-release capsules (CARTIA XT) are administered orally. For hypertension and angina, the typical adult dose is 180–360 mg once daily, initially 180 mg once daily, titrated to response.
Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.
Terminal half-life 3-4.5 hours; prolonged in hepatic impairment (up to 15 hours) or with cimetidine.
Terminal elimination half-life is 3-7 hours for immediate-release; can be prolonged to 12-16 hours with sustained-release due to slow absorption; increased in hepatic impairment.
Primarily hepatic via CYP3A4; extensive first-pass metabolism. Metabolites include desacetyldiltiazem (active, 25-50% potency).
Extensively metabolized in the liver via CYP3A4, CYP1A2, and CYP2C8 isoenzymes; undergoes N-dealkylation and O-demethylation; first-pass metabolism results in low bioavailability (20-35%).
Renal (biliary/fecal minimal). 70-80% excreted as inactive metabolites in urine; 15% unchanged.
Approximately 70% renal (3-4% unchanged, remainder as metabolites) and 25% biliary/fecal.
40-50% bound to albumin.
Approximately 90% bound to plasma proteins, primarily albumin.
Vd 5-10 L/kg; reflects extensive tissue distribution (highly lipophilic).
Vd 4-5 L/kg; indicates extensive tissue distribution beyond plasma volume.
IR: 30-40% (first-pass metabolism); ER (CARTIA XT): 30-40% relative to IR.
Oral bioavailability is 20-35% due to extensive first-pass hepatic metabolism; IV bioavailability is 100%.
No specific dose adjustment is required for renal impairment. However, use with caution in patients with severe renal impairment (Cr Cl <30 m L/min) and monitor heart rate and blood pressure.
Cr Cl <30 m L/min: reduce dose by 50% and monitor carefully.
Contraindicated in acute hepatic injury. For mild to moderate hepatic impairment (Child-Pugh class A/B), reduce starting dose by 50% and titrate slowly. For severe hepatic impairment (Child-Pugh class C), use is not recommended.
Child-Pugh A: 50% of normal dose; Child-Pugh B: 25% of normal dose; Child-Pugh C: contraindicated or use with extreme caution.
Safety and efficacy in pediatric patients have not been established. No standard weight-based dosing guidelines are available.
Oral: 4-8 mg/kg/day in 3 divided doses; IV: 0.1-0.3 mg/kg over 2 minutes, max 5 mg.
In elderly patients (≥65 years), start at the lower end of the dosing range (e.g., 120–180 mg once daily) due to increased potential for bradycardia and hypotension; titrate cautiously.
Start at lowest dose (e.g., 40 mg 3 times daily) and titrate slowly; monitor for hypotension and bradycardia.
None
Contains verapamil hydrochloride. Risk of serious adverse effects including hypotension, bradycardia, AV block, and cardiac arrest. Must not be administered to patients with severe left ventricular dysfunction, cardiogenic shock, or sick sinus syndrome (unless paced).
Heart failure: may worsen systolic function due to negative inotropic effects,Sick sinus syndrome or AV block: risk of bradycardia, heart block,Concomitant beta-blocker use: increased risk of bradycardia, heart failure,Hepatic impairment: reduce dose,Renal impairment: use caution,Abrupt discontinuation: may cause angina exacerbation,Sinus bradycardia: monitor heart rate
May cause hypotension, bradycardia, AV block, and exacerbation of heart failure. Avoid in patients with pre-existing conduction abnormalities. Use caution with beta-blockers, digoxin, and CYP3A4 inhibitors. Abrupt withdrawal may exacerbate angina. May increase lithium and carbamazepine levels.
Hypersensitivity to diltiazem or any component,Sick sinus syndrome (except with functioning pacemaker),Second- or third-degree AV block (except with pacemaker),Left ventricular systolic dysfunction (ejection fraction <40%) with pulmonary congestion,Severe hypotension (systolic BP <90 mm Hg),Concurrent use of ivabradine
Severe left ventricular dysfunction, cardiogenic shock, sick sinus syndrome (without pacemaker), second- or third-degree AV block (without pacemaker), atrial flutter/fibrillation with accessory bypass tract (e.g., WPW syndrome), concurrent use of IV beta-blockers.
Avoid grapefruit and grapefruit juice as they can increase diltiazem levels and risk of side effects. Avoid high-fat meals close to dosing as they may affect absorption. Limit alcohol intake as it may worsen hypotension or dizziness.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing verapamil levels and risk of toxicity. Limit alcohol intake as it may enhance hypotensive effects. High-fat meals may delay absorption but not extent; take consistently with regard to meals.
FDA Pregnancy Category C. First trimester: No adequate studies; potential for embryotoxicity. Second and third trimesters: May cause fetal bradycardia, hypotension, hypoglycemia; risk of intrauterine growth restriction. Use only if benefit outweighs risk.
First trimester: No increased risk of major malformations observed in human studies; animal studies show fetal toxicity at high doses. Second and third trimesters: May cause fetal bradycardia, hypotension, and impaired placental perfusion; avoid use for pregnancy-induced hypertension due to risk of fetal hypoxia.
Diltiazem is excreted in breast milk with a milk-to-plasma ratio of approximately 0.5-1.0. Limited data suggest low risk to infant, but consider monitoring for bradycardia and hypotension. Use with caution.
Verapamil (CALAN) is excreted into breast milk; M/P ratio approximately 0.6. The relative infant dose is low (estimated <5% of maternal weight-adjusted dose). No adverse effects reported in breastfed infants. Caution in preterm infants or those with renal impairment.
No specific dose adjustments recommended; increased clearance in pregnancy may require dose titration based on clinical response. Monitor for hypotension and bradycardia. Use lowest effective dose.
Pregnancy may increase clearance of verapamil; monitoring of therapeutic effect advised. Dose may need adjustment based on clinical response. Avoid use in pregnancy-induced hypertension.
CARTIA XT is a sustained-release formulation of diltiazem, a calcium channel blocker. Avoid use in patients with sick sinus syndrome or second/third-degree AV block without a pacemaker. Titrate slowly to prevent hypotension. Monitor heart rate and blood pressure regularly. Use with caution in hepatic or renal impairment. Can be used for rate control in atrial fibrillation but not for conversion. Swallow capsules whole; do not crush or chew.
Calan (verapamil) is a class IV antiarrhythmic and calcium channel blocker. Use caution in patients with hepatic impairment due to reduced clearance; dose adjustment may be needed. Avoid in patients with pre-existing bradycardia, second- or third-degree AV block, or sick sinus syndrome unless a pacemaker is present. May increase digoxin levels; monitor digoxin concentrations. Use with caution in patients with hypertrophic cardiomyopathy. For IV administration, have calcium gluconate available to reverse hypotension or bradycardia. Not recommended for use in acute myocardial infarction or cardiogenic shock.
Take this medication exactly as prescribed, usually once daily. Swallow the capsule whole; do not crush, chew, or open it.,Do not stop taking this medication suddenly without consulting your doctor, as it may worsen your condition.,Avoid drinking grapefruit juice or eating grapefruit while taking this medication.,Inform your doctor if you experience dizziness, lightheadedness, slow heartbeat, swelling of ankles/feet, or shortness of breath.,This medication may cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Keep a regular schedule for taking this medication to maintain consistent levels in your blood.
Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.,Avoid grapefruit juice as it can increase verapamil levels and risk of side effects.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid alcohol as it may worsen side effects like dizziness or low blood pressure.,Report symptoms of bradycardia (slow heart rate), palpitations, shortness of breath, or swelling of ankles/feet.,This medication may cause dizziness; avoid driving or operating machinery until you know how it affects you.,Do not consume grapefruit or its juice during treatment.,Keep a regular medication schedule and do not change brands without doctor approval.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARTIA XT vs CALAN, answered by our medical review team.
CARTIA XT is a Calcium Channel Blocker that works by Diltiazem, a benzothiazepine calcium channel blocker, inhibits calcium ion influx across cardiac and vascular smooth muscle cells during depolarization, leading to vasodilation and reduced myocardial contractility and conduction velocity, particularly at the AV node.. CALAN is a Calcium Channel Blocker that works by Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARTIA XT and CALAN depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARTIA XT is: Diltiazem hydrochloride extended-release capsules (CARTIA XT) are administered orally. For hypertension and angina, the typical adult dose is 180–360 mg once daily, initially 180 mg once daily, titrated to response.. The standard adult dose of CALAN is: Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARTIA XT and CALAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARTIA XT is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate studies; potential for embryotoxicity. Second and third trimesters: May cause fetal bradycardia, hypotension, hypoglycemia; r. CALAN is classified as Category C. First trimester: No increased risk of major malformations observed in human studies; animal studies show fetal toxicity at high doses. Second and third trimesters: May cause fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.